Avidity Biosciences Inc
RNA69.780USD
-0.020-0.03%
收盘 11/06, 16:00（美东）报价延迟15分钟
8.43B总市值
亏损市盈率 TTM
关于 Avidity Biosciences Inc 公司
Avidity Biosciences, Inc. 是一家生物制药公司。该公司致力于提供一种称为抗体寡核苷酸偶联物 (AOC) 的新型核糖核酸 (RNA) 疗法。AOC 旨在将单克隆抗体的特异性与寡核苷酸疗法的精确性相结合，以解决现有 RNA 疗法以前无法触及的目标和疾病。其不断推进和扩展的管道有三个临床开发项目。AOC 1001 旨在治疗患有 1 型肌强直性营养不良症 (DM1) 的人，并且与正在进行的 MARINA 开放标签扩展研究 (MARINA-OLE) 一起处于 I/II 期开发阶段。AOC 1044 专为杜氏肌营养不良症患者设计，并且与 EXPLORE44 试验一起处于 I/II 期开发阶段。 AOC 1020 旨在治疗面肩肱型肌营养不良症 (FSHD) 患者，目前正与 FORTITUDE 试验一起处于 I/II 期开发阶段。
Avidity Biosciences Inc简介
公司代码RNA
公司名称Avidity Biosciences Inc
上市日期Jun 12, 2020
CEOMs. Sarah Boyce
员工数量391
证券类型Ordinary Share
年结日Jun 12
公司地址10578 Science Center Drive
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编92121
电话18584017900
网址https://www.aviditybiosciences.com/
公司代码RNA
上市日期Jun 12, 2020
CEOMs. Sarah Boyce
Avidity Biosciences Inc公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Sarah Boyce
Ms. Sarah Boyce
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
423.43K
--
Ms. Teresa Mccarthy
Ms. Teresa Mccarthy
Chief Human Resources Officer
Chief Human Resources Officer
98.09K
--
Ms. Kathleen P. Gallagher
Ms. Kathleen P. Gallagher
Chief Program Officer
Chief Program Officer
49.45K
-0.38%
Mr. John B. Moriarty
Mr. John B. Moriarty
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
47.76K
-4.49%
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
6.69K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
6.69K
--
Mr. Carsten Boess
Mr. Carsten Boess
Independent Director
Independent Director
6.69K
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Independent Director
Independent Director
6.69K
--
Dr. W. Michael Flanagan, Ph.D.
Dr. W. Michael Flanagan, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Eric B. Mosbrooker
Mr. Eric B. Mosbrooker
Chief Commercial Officer
Chief Commercial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Sarah Boyce
Ms. Sarah Boyce
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
423.43K
--
Ms. Teresa Mccarthy
Ms. Teresa Mccarthy
Chief Human Resources Officer
Chief Human Resources Officer
98.09K
--
Ms. Kathleen P. Gallagher
Ms. Kathleen P. Gallagher
Chief Program Officer
Chief Program Officer
49.45K
-0.38%
Mr. John B. Moriarty
Mr. John B. Moriarty
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
47.76K
-4.49%
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
6.69K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
6.69K
--
收入明细
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
暂无数据
地区USD
名称
营收
占比
United States
3.85M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
10.77%
The Vanguard Group, Inc.
9.00%
Janus Henderson Investors
8.26%
T. Rowe Price Associates, Inc.
7.26%
Wellington Management Company, LLP
6.30%
其他
58.42%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
10.77%
The Vanguard Group, Inc.
9.00%
Janus Henderson Investors
8.26%
T. Rowe Price Associates, Inc.
7.26%
Wellington Management Company, LLP
6.30%
其他
58.42%
股东类型
持股股东
占比
Investment Advisor
41.50%
Investment Advisor/Hedge Fund
34.92%
Venture Capital
5.99%
Research Firm
4.87%
Hedge Fund
3.94%
Corporation
3.45%
Private Equity
1.69%
Individual Investor
0.77%
Sovereign Wealth Fund
0.68%
其他
2.19%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
511
143.66M
99.26%
-2.09M
2025Q2
498
141.72M
117.38%
-3.41M
2025Q1
508
142.16M
117.97%
-7.67M
2024Q4
492
135.01M
112.33%
-12.86M
2024Q3
467
132.62M
112.76%
+3.34M
2024Q2
414
118.94M
111.18%
+14.23M
2024Q1
365
96.48M
102.78%
+1.47M
2023Q4
345
83.09M
112.13%
-13.56M
2023Q3
334
86.17M
118.19%
-15.24M
2023Q2
328
86.81M
124.27%
-3.56M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
15.82M
11.65%
+525.77K
+3.44%
Jun 30, 2025
The Vanguard Group, Inc.
9.23M
6.8%
+5.10K
+0.06%
Jun 30, 2025
Janus Henderson Investors
12.13M
8.94%
+1.35M
+12.57%
Jul 31, 2025
T. Rowe Price Associates, Inc.
10.67M
7.86%
-537.26K
-4.79%
Jun 30, 2025
Wellington Management Company, LLP
9.25M
6.81%
-434.87K
-4.49%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.18M
6.03%
-213.56K
-2.54%
Jun 30, 2025
RA Capital Management, LP
7.27M
5.35%
+965.62K
+15.33%
Jun 30, 2025
Avoro Capital Advisors LLC
7.05M
5.19%
-575.00K
-7.54%
Jun 30, 2025
Bristol Myers Squibb
5.08M
3.74%
--
--
Sep 30, 2024
RTW Investments L.P.
9.62M
7.08%
+871.92K
+9.97%
Jun 30, 2025
查看更多
持股ETF
更新时间: 22 小时前
更新时间: 22 小时前
机构名称
占比
Global X Genomics & Biotechnology ETF
5.05%
ALPS Medical Breakthroughs ETF
3.8%
SPDR S&P Biotech ETF
1.94%
Tema Heart & Health ETF
1.05%
Direxion Daily S&P Biotech Bull 3X Shares
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
JPMorgan Healthcare Leaders ETF
0.59%
ProShares Ultra Nasdaq Biotechnology
0.58%
Invesco Nasdaq Biotechnology ETF
0.57%
iShares Biotechnology ETF
0.48%
查看更多
Global X Genomics & Biotechnology ETF
占比5.05%
ALPS Medical Breakthroughs ETF
占比3.8%
SPDR S&P Biotech ETF
占比1.94%
Tema Heart & Health ETF
占比1.05%
Direxion Daily S&P Biotech Bull 3X Shares
占比1.02%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.98%
JPMorgan Healthcare Leaders ETF
占比0.59%
ProShares Ultra Nasdaq Biotechnology
占比0.58%
Invesco Nasdaq Biotechnology ETF
占比0.57%
iShares Biotechnology ETF
占比0.48%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
